AKT1 and nonpapillary renal cell carcinoma: In addition to the aforementioned effect on the AKT pathway, miR-182-5p acts as an inhibitor of its target HIF2A, even though it is primarily manifest in VHL-deficient ccRCC cells (Fan Y. et al., 2016).